Using AI to predict liver fibrosis severity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a non-invasive intelligent grading diagnosis system for liver fibrosis using deep learning techniques. Patients with chronic hepatitis B will undergo liver biopsy, and their clinical, imaging, and biochemical data will be analyzed alongside data from healthy volunteers. The study employs a convolutional neural network (CNN) to extract relevant features from multi-modal data, aiming to accurately classify the severity of liver fibrosis. By leveraging a large dataset collected over four years, the study seeks to improve diagnostic accuracy and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age of 18-60 years old
2. The diagnosis of chronic hepatitis B is in line with the diagnostic criteria of China's 2019 Chronic Hepatitis B Prevention and Treatment Guidelines, and the diagnosis of non-alcoholic fatty liver is in line with the Asian Pacific Hepatology Association guidelines
3. Imaging showed no liver cancer

Exclusion Criteria:

1. There are contraindications for liver biopsy
2. Liver pathology did not meet the criteria

Where it's running

• Haijun Huang
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Haijun Huang
• Email: huanghaijun0826@163.com
• Phone: 13758186635

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• Umbilical cord stem cells added during Kasai to help biliary atresia

  This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta · NCT07797673

• Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD

  This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07658755

• AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring

  This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.

  Recruiting at 22 sites Phase 2 AstraZeneca · Chandler, Arizona and 21 other locations · NCT07610837

• See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease

  This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07588854

• Non-invasive liver fibrosis testing in children and young adults with type III glycogen storage disease

  This project tries to see if non-invasive liver stiffness measurements (like elastography) can monitor liver fibrosis in children and young adults with type III glycogen storage disease.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07303140

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.